Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System.

ABSTRACT:

Objects

Tepotinib is widely utilized for treating non-small cell lung cancer (NSCLC) patients with MET exon 14 (METex14) skipping mutations. The purpose of this study is to evaluate the safety characteristics of Tepotinib in the actual environment by analyzing data from the Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Methods

This study analyzed adverse event (AE) reports related to Tepotinib from FAERS database spanning Q1 2021 to Q4 2024. Four disproportionality analysis methods were employed: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Multi-Item Gamma Poisson Shrinker (MGPS), and Bayesian Confidence Propagation Neural Network (BCPNN). A descriptive analysis and a subgroup analysis of the time to onset (TTO) of AEs was

SUBMITTER: Wei S 

PROVIDER: S-EPMC12714243 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature